Mutations on PTEN and PI3KCA gene also contribute to the resistance of tumor cells of mAbs Trastuzumab, Lapatinib and Pertuzumab in HER2+ BC, causing the relapse or metastases of the tumor [3,4,18]. This evidence concerns the gene ERBB2 and breast cancer.